Journal article

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy

Abstract:: Background: Somatostatin receptor-2 (SSTR2) is expressed on cell surface of neuroendocrine neoplasias; its presence is exploited for the delivery of peptide receptor radionuclide therapy (PRRT). Patients with no or low expression of SSTR2 are not candidates for PRRT. SSTR2 promotor undergoes epigenetic modification, known to regulate gene expression. We investigated whether the demethylation agent, guadecitabine, could enhance the expression of SSTR2 in NET models, us...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Evans, J. S., Beaumont, J., Braga, M., Masrour, N., Mauri, F., Beckley, A., Butt, S., Karali, C. S., Cawthorne, C., Archibald, S., Aboagye, E. O., & Sharma, R. (2022). Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. European Journal of Cancer, 176, 110–120.

MLA Style

Evans, J. S., et al. “Epigenetic Potentiation of Somatostatin-2 by Guadecitabine in Neuroendocrine Neoplasias as a Novel Method to Allow Delivery of Peptide Receptor Radiotherapy.” European Journal of Cancer, vol. 176, Elsevier, 2022, pp. 110–20.

Chicago Style

Evans, JS, J Beaumont, M Braga, N Masrour, F Mauri, A Beckley, S Butt, et al. 2022. “Epigenetic Potentiation of Somatostatin-2 by Guadecitabine in Neuroendocrine Neoplasias as a Novel Method to Allow Delivery of Peptide Receptor Radiotherapy.” European Journal of Cancer 176: 110–20.
Tweet
Print

Access Document

Files:: Evans_et_al_2022_Epigenetic_potentiation_of.pdf

(Preview, Version of record, pdf, 792.7KB, Terms of use)

Publisher copy:: 10.1016/j.ejca.2022.09.009

Authors

+ Evans, JS More by this author

Role:

Author

+ Beaumont, J More by this author

Role:

Author

+ Braga, M More by this author

Role:

Author

+ Masrour, N More by this author

Role:

Author

+ Mauri, F More by this author

Role:

Author

More authors...

Funding

+ Medical Research Council More from this funder

Grant:

MR/J007986/1

Bibliographic Details

Publisher:: Elsevier
Journal:: European Journal of Cancer More from this journal
Volume:: 176
Pages:: 110-120
Publication date:: 2022-10-05
Acceptance date:: 2022-09-08
DOI:: 10.1016/j.ejca.2022.09.009
EISSN:: 1879-0852
ISSN:: 0959-8049
Pmid:: 36208569

Item Description

Language:: English
Keywords:: neuroendocrine tumours

SBTMR

guadecitabine

peptide receptor radionuclide therapy

SSTR2

epigenetic modification
Pubs id:: 1997770
Local pid:: pubs:1997770
Deposit date:: 2024-05-21

Terms of use

Copyright holder:: Crown
Copyright date:: 2022
Rights statement:: Crown Copyright © 2022 Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).

Licence:: CC Attribution (CC BY)

Metrics

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP